PARP1 and Miyoshi myopathy: This was also substantiated by Alagpulinsa et al., where the researchers showed that co-treatment of MM cells with Dinaciclib and ABT-888, a cyclin-kinase dependent inhibitor and a PARP1/2 Inhibitor respectively, in vitro resulted in synthetic lethality of MM cells but not normal B cells and slowed the growth of MM xenografts in SCID mice almost by two-fold [103].